Trial Profile
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jun 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Sirexatamab (Primary)
- Indications Carcinoma; Endometrial cancer; Gynaecological cancer; Ovarian cancer; Sarcoma; Uterine cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Leap Therapeutics
- 29 Mar 2023 Results of a phase 2 basket study in women with recurrent endometrial carcinoma published in the Gynecologic Oncology
- 09 Sep 2021 Status changed from active, no longer recruiting to completed.
- 14 May 2021 According to a Leap Therapeutics media release, results from this study presented in Leap Therapeutics financial media release.